Ribosomopathies result in various cancers, neurodegenerative and viral diseases, and other pathologies such as Diamond–Blackfan anemia and Shwachman–Diamond syndrome. Their pathophysiology at a proteome and functional level remains to be determined. Protein networks and highly connected hub proteins for ribosome biogenesis in Saccharomyces cerevisiae offer a potential as a model system to inform future therapeutic innovation in ribosomopathies. In this context, we report a ribosome biogenesis protein–protein interaction network in S. cerevisiae, created with 1772 proteins and 22,185 physical interactions connecting them. Moreover, by network decomposition analysis, we determined the linear pathways between the transcription factors and target proteins with a view to drug repurposing. While considering only the paths containing the three C/D box proteins (Nop56, Nop58, and Nop1), the most frequently encountered proteins were Aft1, Htz1, Ssa1, Ssb1, Ssb2, Gcn5, Cka1, Tef1, Nop1, Cdc28, Act1, Krr1, Rpl8B, and Tor1, which were then identified as potential drug targets. For drug repurposing, these candidate proteins were further searched in the DrugBank to find other diseases associated with them, as well as the drugs used to treat these diseases. To support the computational results, an experimental study was conducted using in-house manufactured microfluidic bioreactor platform, while the effect of the drug temsirolimus, Tor1 inhibitor, on yeast cells was investigated by following Nop56 protein expression. In conclusion, these results inform the ways in which ribosomopathies and associated common complex human diseases materialize and how drug repurposing might accelerate therapeutic innovation through bioinformatic studies of yeast.
ArgaKY, OnsanZI, KirdarB, UlgenKO, and NielsenJ. (2007). Understanding signaling in yeast: Insights from network analysis. Biotechnol Bioeng, 97, 1246–1258.
5.
AyscoughKR, StrykerJ, PokalaN, SandersM, CrewsP, and DrubinDG. (1997). High rates of actin filament turnover in budding yeast and roles for actin in establishment and maintenance of cell polarity revealed using the actin inhibitor latrunculin-A. J Cell Biol, 137, 399–416.
6.
BaderGD, and HogueCWV. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4, 2.
BarabásiAL, and OltvaiZN. (2004). Network biology: Understanding the cell's functional organization. Nat Rev Genet, 5, 101–113.
9.
BlenisJ. (2017). TOR, the gateway to cellular metabolism, cell growth, and disease. Cell, 171, 10–13.
10.
BoyleEI, WengS, GollubJ, et al. (2004). GO::TermFinder—Open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics, 20, 3710–3715.
DayanIE, ArgaKY, and UlgenKO. (2017). Multi-omics approach to novel therapeutic targets for cancer and aging related diseases: Role of Sld7 in yeast aging network. OMICS, 21, 100–113.
13.
De BoerP, VosHR, FaberAW, VosJC, and RauéHA. (2006). Rrp5p, a trans-acting factor in yeast ribosomem biogenesis, is an RNA-binding protein with a pronounced preference for U-rich sequences. RNA, 12, 263–271.
14.
Durmuş TekirS, ÜmitP, TokuAE, and ÜlgenKÖ. (2010). Reconstruction of protein-protein interaction of insulin signaling in Homo sapiens. J Biomed Biotechnol, 2010, 690925.
15.
Durmuş TekirS, Yalçin ArgaK, and ÜlgenKÖ. (2009). Drug targets for tumorigenesis: Insights from structural analysis of EGFR signaling network. J Biomed Inform, 42, 228–236.
16.
EkmanD, LightS, Björklund ÅK, and ElofssonA. (2006). What properties characterize the hub proteins of the protein-protein interaction network of Saccharomyces cerevisiae?. Genome Biol, 7, 1–13.
FagoneP, DoniaM, ManganoK, et al. (2013). Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol, 112, 63–69.
19.
FishmanJA, and KarnovskyMJ. (1985). Effects of aminonucleoside puromycin on glomerular epithelial cells in vitro. Am J pathol, 118, 398–407.
FurutaN, TsukagoshiS, HirayanagiK, and IkedaY. (2019). Suppression of the yeast elongation factor Spt4 ortholog reduces expanded SCA36 GGCCUG repeat aggregation and cytotoxicity. Brain Res, 1711, 29–40.
23.
García-MuriasM, QuintánsB, AriasM, et al. (2012). “Costa da Morte” ataxia is spinocerebellar ataxia 36: Clinical and genetic characterization. Brain, 135, 1423–1435.
24.
GautierT, BergesT, TollerveyD, and HurtE. (1997). Nucleolar KKE/D repear proteins Nop56p and Nop58p interact with Nop1p and are required for ribosome biogenesis. Mol Cell Biol, 17, 7088–7098.
25.
GethingMJ. (1997). Guidebook to Molecular Chaperons and Protein-Folding Catalysts. OUP/Sambrook and Tooze Publications. Oxford University Press.
HuZ, KillionPJ, and IyerVR. (2007). Genetic reconstruction of a functional transcriptional regulatory network. Nat Genet, 39, 683–687.
28.
JeongH, MasonSP, BarabásiAL, and OltvaiZN. (2001). Lethality and centrality in protein networks. Nature, 411, 41.
29.
JinY, Messmer-BlustAF, and LiJ. (2011). The role of transcription enhancer factors in cardiovascular biology. Trends Cardiovasc Med, 21, 1–5.
30.
KaragozK, and ArgaKY. (2013). Assessment of high-confidence protein-protein interactome in yeast. Comput Biol Chem, 45, 1–8.
31.
KimJ, and GuanKL. (2019). Mtor as a central hub of nutrient signalling and cell growth. Nat Cell Biol, 21, 63–71.
32.
KlumpenH-J, BeijnenJH, GurneyH, and SchellensJHM. (2010). Inhibitors of Mtor. Oncologist, 15, 1262–1269.
33.
KobayashiH, AbeK, MatsuuraT, et al. (2011). Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet, 89, 121–130.
34.
KonishiH, KikuchiS, OchiaiT, et al. (2009). Latrunculin A has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res, 29, 2091–2097.
35.
LiuY, and ChangA. (2009). A mutant plasma membrane protein is stabilized upon loss of Yvh1, a novel ribosome assembly factor. Genetics, 181, 907–915.
36.
LoewithR, and HallMN. (2011). Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics, 189, 1177–1201.
37.
MaereS, HeymansK, and KuiperM. (2005). BiNGO: A Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks. Bioinformatics, 21, 3448–3449.
38.
MariappanMM, D'SilvaK, LeeMJ, et al. (2011). Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells. Am J Physiol Physiol, 300, F219–F230.
39.
MendenhallMD, and HodgeAE. (1998). Regulation of Cdc28 cyclin-dependent protein kinase activity during the cell cycle of the yeast Saccharomyces cerevisiae. Microbiol Mol Biol Rev, 62, 1191–243.
40.
MeyerCG, and St. ClairEW. (2009). Promising Biologic Agents and Small Chemical Compounds. In Rheumatoid Arthritis. Ed: HachbergMC, et al. pgs. 372–378.
41.
MillsEW, and GreenR. (2017). Ribosomopathies: There's strength in numbers. Science. 358.
42.
NalbantogluB, Durmuş TekirS, and ÜlgenK. (2012). Wnt signaling network in Homo sapiens. In Cell Metabolism—Cell Homeostasis Stress Response. Ed: BubulyaP; pgs. 163–180.
43.
NarlaA, and EbertBL. (2010). Ribosomopathies: Human disorders of ribosome dysfunction. Blood, 115, 3196–3205.
44.
NelsonRJ, ZiegelhofferT, NicoletC, Werner-WashburneM, and CraigEA. (1992). The translation machinery and 70 kd heat shock protein cooperate in protein synthesis. Cell, 71, 97–105.
PalanivelK, KanimozhiV, KadalmaniB, and AkbarshaMA. (2013). Verrucarin A, a protein synthesis inhibitor, induces growth inhibition and apoptosis in breast cancer cell lines MDA-MB-231 and T47D. Biotechnol Lett, 35, 1395–1403.
48.
PfundC, HuangP, Lopez-hoyoN, and CraigEA. (2001). Divergent functional properties of the ribosome-associated molecular chaperone Ssb compared with other Hsp70s. Mol Biol Cell, 12, 3773–3782.
49.
PolymenisM, and AramayoR. (2015). Translate to divide: Control of the cell cycle by protein synthesis. Microb Cell, 2, 94–104.
50.
PowersT, and WalkerP. (1999). Regulation of ribosome biogenesis by the rapamycin-sensitive TOR signaling pathway in Saccharomyces cerevisiae. Mol Biol Cell, 10, 987–1000.
RajeN, KumarS, HideshimaT, et al. (2005). Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood, 106, 1042–1047.
53.
RakwalskaM, and RospertS. (2004). The ribosome-bound chaperones RAC and Ssb1/2p are required for accurate translation in Saccharomyces cerevisiae. Mol Cell Biol, 24, 9186–9197.
54.
RaynaudFI, WhittakerSR, FischerPM, et al. (2005). In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res, 11, 4875–4888.
55.
RiniBI. (2008). Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res, 14, 1286–1290.
56.
RojasM, CasadoM, PortugalJ, and PiñaB. (2008). Selective inhibition of yeast regulons by daunorubicin: A transcriptome-wide analysis. BMC Genomics, 9, 1–16.
57.
RussoA, and RussoG. (2017). Ribosomal proteins control or bypass p53 during nucleolar stress. Int J Mol Sci, 18, 1–16.
58.
SchirmaierF, and PhilippsenP. (1984). Identification of two genes coding for the translation elongation factor EF-1 alpha of S. cerevisiae. EMBO J, 3, 3311–3315.
59.
SmithJD, TrautRR, BlackburnGM, and MonroRE. (1965). Action of puromycin in polydenylic acid-directed polylysine synthesis. J Mol Biol, 13, 617–628.
60.
SmootME, OnoK, RuscheinskiJ, WangPL, and IdekerT. (2011). Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics, 27, 431–432.
61.
SteffenM, PettiA, AachJ, D'haeseleerP, and ChurchG. (2002). Automated modelling of signal transduction networks. BMC Bioinformatics, 3, 1–11.
TadakaS, and KinoshitaK. (2016). NCMine: Core-peripheral based functional module detection using near-clique mining. Bioinformatics, 32, 3454–3460.
64.
TangZ, XingF, ChenD, et al. (2012). In vivo toxicological evaluation of Anisomycin. Toxicol Lett, 208, 1–11.
65.
TessarzP, Santos-RosaH, RobsonSC, et al. (2014). Glutamine methylation in Histone H2A is an RNA Polymerase I dedicated modification. Nature, 505, 564–568.
66.
ThomsonE, Ferreira-CercaS, and HurtE. (2013). Eukaryotic ribosome biogenesis at a glance. J Cell Sci, 126, 4815–4821.
67.
TokuAE, DurmusS, BetülF, ÖzbayraktarK, and ÜlgenKÖ. (2011). Reconstruction and crosstalk of protein—protein interaction networks of Wnt and Hedgehog signaling in Drosophila melanogaster. Comput Viol Chem, 35, 282–292.
WattsD, and StrogatzS. (1998). Collective dynamics of networks. Nature, 393, 440–442.
70.
WeiY, and ZhengS. (2009). Sch9 partially mediates TORC1 signaling to control ribosomal RNA synthesis. Cell Cycle, 8, 4085–4090.
71.
WeinblattME, KavanaughA, GenoveseMC, MusserTK, GrossbardEB, and MagilavyDB. (2010). An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med, 363, 1303–1312.
72.
WeinblattME, KavanaughA, GenoveseMC, et al. (2013). Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol, 40, 369–378.
73.
Werner-WashburneM, StoneDE, and CraigEA. (1987). Complex interactions among members of an essential subfamily of hsp70 genes in Saccharomyces cerevisiae. Mol Cell Biol, 7, 2568–77.
74.
WoolfordJLJr., and BasergaSJ. (2013). Ribosome biogenesis in the yeast Saccharomyces cerevisiae. Genetics, 195, 643–681.
75.
WuX, ZhuY, and LiY. (2005). Analyzing protein interaction networks via random graph model. Int J Inf Technol Decis Mak, 11, 125–132.
76.
WullschlegerS, LoewithR, and HallMN. (2006). TOR signaling in growth and metabolism. Cell, 124, 471–484.
77.
YanF, YuY, ChowDC, et al. (2014). Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One, 9, 1–9.
YazbeckVY, BuglioD, GeorgakisGV, et al. (2008). Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol, 36, 443–450.
80.
YoshimiR, UedaA, OzatoK, and IshigatsuboY. (2012). Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol, 2012, 606195.
81.
YuH, KimPM, SprecherE, TrifonovV, and GersteinM. (2007). The importance of bottlenecks in protein networks: Correlation with gene essentiality and expression dynamics. PLoS Comput Biol, 3, 713–720.
82.
ZhangCJ, WangC, JiangM, et al. (2018). Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. Nat Commun, 9, 2745.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
